Document is current
Any future updates will be listed below
-
Authors
Kallás, Esper G.
Moreira, José A.
Patiño, Elizabeth G.
Braga, Patricia Emilia
Tenório, Juliana C. V.
Alves, Lucas Bassolli de Oliveira
Infante, Vanessa
Silveira, Daniela Haydee Ramos
Miraglia, João Luiz
Cintra, Monica A. T.
Pereira, Dhelio Batista https://orcid.org/0000-0002-7761-5498
da Fonseca, Allex Jardim
Gurgel, Ricardo Queiroz
Coelho, Ivo Castelo-Branco
Fontes, Cor Jesus Fernandes https://orcid.org/0000-0003-2756-0588
Marques, Ernesto T. A. https://orcid.org/0000-0003-3826-9358
Romero, Gustavo Adolfo Sierra https://orcid.org/0000-0003-1425-926X
Teixeira, Mauro Martins https://orcid.org/0000-0002-6944-3008
Siqueira, André M. https://orcid.org/0000-0003-2208-0294
Boaventura, Viviane Sampaio https://orcid.org/0000-0002-7241-6844
Ramos, Fabiano
Júnior, Erivaldo Elias
Cassio de Moraes, José
Estofolete, Cássia Fernanda https://orcid.org/0000-0001-7324-1591
Freitas, Angela Carvalho
dos Santos, Cecilia Luiza Simoes
Timenetsky, Maria do Carmo S. T.
Whitehead, Stephen S. https://orcid.org/0000-0001-6707-482X
Durbin, Anna P. https://orcid.org/0000-0002-6652-2851
Esteves-Jaramillo, Alejandra https://orcid.org/0000-0002-6165-197X
Shekar, Tulin
Lee, Jung-Jin
Chen, Qiuxu
Macey, Julieta
Vaidya, Sanskruti
Coller, Beth-Ann G.
Boulos, Fernanda Castro https://orcid.org/0009-0001-9388-9210
Nogueira, Mauricio L. https://orcid.org/0000-0003-1102-2419
Lacerda, Marcus Vínicius Guimarães de
- License Information
-
More Information
Article History
Received: 12 August 2025
Accepted: 30 January 2026
First Online: 4 March 2026
Competing interests
: E.G.K., J.A.M., E.G.P., P.E.B., J.C.V.T., L.B.O.A., V.I., D.H.R.S., J.L.M. and F.C.B. are employees of Instituto Butantan. M.A.T.C. was an employee of Instituto Butantan when the trial took place. E.G.K. is the current director of Instituto Butantan. F.C.B. reports owning stock from Novartis. Instituto Butantan, a nonprofit public health institution, provided research grants used by the site institutions to fund the clinical trial. S.S.W. reports that the vaccine technology was licensed by Butantan Foundation/Institute from his employer (National Institutes of Health). A.P.D. is a consultant with Merck & Co., advising them on dengue vaccine development. A.E.-J., T.S., J.-J.L., D.C., S.V., J.M. and B.-A.G.C. are (or were) employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock and/or hold stock option in Merck & Co., Inc., Rahway, NJ, USA. D.B.P., A.J.d.F., R.Q.G., I.C.-B.C., C.J.F.F., E.T.A.M., G.A.S.R., M.M.T., A.M.S., V.S.B., F.R., E.E., J.C.M., C.F.E., A.C.F., C.L.S.d.S., M.C.S.T.T., M.L.N. and M.V.G.L. declare no competing interests.
